In this episode, Darcey Wooten, MD, discusses the long-acting HIV treatment agent lenacapavir for treatment-experienced people with HIV, including:Efficacy dataInitiation strategiesVirologic failure dataSafety informationPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaTo download the slides:http://bit.ly/3Jb1ofXTo view the full online program:https://bit.ly/3ZjSFhg

In this episode, Darcey Wooten, MD, discusses updated guidance and rationale for monitoring for new HIV infections in people receiving long-acting PrEP, including:Testing both Ag/Ab and HIV-1 RNASteps to take when a person receiving long-acting PrEP develops a new HIV infectionPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaTo download the slides:https://bit.ly/3Jb1ofXTo view the full online program:https://bit.ly/3ZjSFhg

In this episode, Coleman I. Smith, MD, and Lydia Tang, MBChB, discuss how to screen for hepatitis delta virus (HDV), including:Algorithm for evaluation of HDVDiagnosis of different stages of HDV infection Strategies to increase HDV testing rates Faculty:Coleman I. Smith, MDProfessor of MedicineHepatologistGeorgetown Transplant InstituteGeorgetown UniversityWashington, DCLydia Tang, MBChB Assistant ProfessorDepartment of Infectious DiseasesUniversity of Maryland School of MedicineInstitute of Human VirologyBaltimore, MarylandLink to full program:http://bit.ly/41oYawrFollow along with the slides at: http://bit.ly/3XW6m4g

In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)Optimizing the use of the Antiretroviral Pregnancy RegistryAddressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)Faculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public Health University of California, San DiegoSan Diego, CaliforniaWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious Diseases Department of Medicine  Perelman School of Medicine at the University of Pennsylvania Philadelphia, PennsylvaniaLink to full program:http://bit.ly/3PM3nYeLink to downloadable slides: http://bit.ly/3WgYycz

In this episode, Nancy Reau, MD, and Lydia Tang, MBChB, discuss how to increase linkage to care rates for persons with hepatitis D virus, including:Updates on currently low rates of linkage to careBarriers preventing patients with HBV/HDV coinfection from engaging in careInterventions to increase retention in care for patients with HDV Faculty: Nancy Reau, MDProfessor of MedicineChief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisLydia Tang, MBChB Assistant ProfessorDepartment of Infectious DiseasesUniversity of Maryland School of MedicineInstitute of Human VirologyBaltimore, MarylandLink to full program: https://bit.ly/41oYawrFollow along with the slides at: https://bit.ly/3XW6m4g

In this episode, Canadian HIV experts share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.Specifically, the faculty discuss treatment strategies for patients with a history of NRTI resistance based on findings from the 2SD and NADIA trials; the latest data informing the use of 2-drug oral and injectable treatment regimens; prevention approaches for HIV and other sexually transmitted infections based on findings from the DoxyPEP, HPTN 083, and HPTN 084 trials; and other emerging innovations in HIV care.Presenters:Jean-Guy Baril, MDAssociate ProfessorFamily MedicineUniversité de MontrealMontreal, Quebec, CanadaAlexander Wong MD, FRCPCAssociate ProfessorDepartment of MedicineUniversity of SaskatchewanRegina, Saskatchewan, CanadaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E

In this episode, 2 HIV experts from Latin America share their thoughts on the current status of HIV prevention strategies in the region, including recent successes and ongoing challenges. Specifically, the faculty discuss:Barriers that limit PrEP availability in many regions of Latin America despite the high need among vulnerable and at-risk groupsSuccessful expansion of PrEP access in BrazilKey findings from the prospective ImPrEP study evaluating implementation of same-day oral PrEP among men who have sex with men and transgender women in Brazil, Mexico, and PeruWhat long-acting PrEP could mean for at-risk groups in Latin America when it becomes availableImportant considerations for PrEP among TGW Presenters:Claudia P. Cortes MDAssociate ProfessorInfectious DiseasesUniversidad de ChileSantiago, ChileBeatriz Grinsztejn MD, PhD Diretora, STD/HIV Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro ChagasOswaldo Cruz Foundation Rio de Janeiro, BrazilContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E

 In this episode, 2 Australian HIV experts share their thoughts on some of the most important HIV insights gained during the past year in the context of HIV care in Australia.Specifically, the faculty discuss the continued dominance of second-generation INSTI-based regimens as mainstay HIV therapy in Australia, including in both 2-drug and 3-drug oral regimens; the emergence of 2-drug long-acting injectable therapy as a switch strategy; key aspects of successfully expanded oral PrEP programs in the region; the potential role of long-acting injectable PrEP; and key new advances in HIV cure research.  Presenters:Sharon R. Lewin, AO, FRACP, PhD, FAHMSDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesUniversity of Melbourne  Consultant Infectious Diseases PhysicianAlfred Hospital and Royal Melbourne Hospital  Melbourne, AustraliaDon Smith, MDConjoint ProfessorSchool of Population MedicineUniversity of New South WalesSenior Staff SpecialistAlbion CentreSouth Eastern Sydney Local Health NetworkSydney, AustraliaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  Link to full program:http://bit.ly/3YD8T4E  

In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.Presenters:Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyAlexandra Calmy, MD, FMH, PhDHIV/AIDS Unit DirectorInfectious Diseases DivisionGeneva University HospitalsUniversity of GenevaGeneva, SwitzerlandContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.Link to full program:http://bit.ly/3Hz0jNa

In this episode, Alba Azola, MD, and Monica Verduzco-Gutierrez, MD, discuss diagnosis and management of long COVID, including: Definitions of post COVID conditionsDiagnosis, including symptoms and clinical presentationEpidemiologyRisk factorsPossible treatment optionsClinical guidance statementsPresenters:Alba Azola, MDAssistant ProfessorDepartment of Physical Medicine and RehabilitationJohns HopkinsCo-DirectorJohns Hopkins Post Acute COVID Team ClinicBaltimore, MarylandMonica Verduzco-Gutierrez, MDProfessor and Distinguished ChairDepartment of Rehabilitation MedicineUniversity of Texas Health Science Center at San AntonioDirector, UT Health COVID-19 Recovery ClinicDepartment of Rehab MedicineUT Health San AntonioSan Antonio, TexasLink to full program:https://bit.ly/3Gn4tXOLinks to Consensus Guidance Statements on Assessment and Treatment of Post-Acute Sequelae of COVID-19:Autonomic Dysfunction:https://bit.ly/3GHeUGYCardiovascular Complications:https://bit.ly/3CmupkXCognitive Symptoms:https://bit.ly/3X9tnkwFatigue:https://bit.ly/3ihiLRQRespiratory Sequelae: https://bit.ly/3IrUkMc

In this episode, Kenric Ware, PharmD, AAHIVP, discusses the role of college campuses in HIV pre-exposure prophylaxis (PrEP) uptake for adolescents, including the following.PrEP awareness and educationVenues for ongoing PrEP conversations, including in-person dormitory discussions, virtual webinars, and social media conversationsCampus health clinics that are safe and trusting and minimize stigmaIndividualized approaches, including:Engaging local students in discussions of regional barriers and facilitators to PrEP uptake on their campusRecruiting PrEP ambassadors with social capital on campus, such as student athletes or sorority or fraternity leadersIdentifying faculty and administrator PrEP champions to amplify and provide continuity and support to student PrEP messagingKenric Ware, PharmD, AAHIVPAssociate ProfessorDepartment of Pharmacy Practice South UniversitySavannah, GeorgiaChairperson, PharmacistBoard of DirectorsJoseph H. Neal Health CollaborativeColumbia, South Carolina See the full program at: http://bit.ly/3WhbBvZ

In this episode, Eric Florence, MD, PhD, discusses how clinics can prepare for the implementation of long-acting injectable antiretroviral therapy, including:Clinical infrastructureEnsuring adequate space and injection equipmentMaintaining drug supply and temperature requirementsStaffingEnsuring there are staff able to focus on the implementation of LA ART, including well-trained nurses to administer the injectionsImplementing a system for scheduling follow-up injections and providing patient remindersHaving knowledgeable staff available to answer patient questions on their LA ARTEric Florence, MD, PhDPhysicianInternal Medicine, Infectious Diseases & Tropical MedicineUniversity Hospital of AntwerpEdegem, Brussels, BelgiumSee the full program at: https://bit.ly/3CsSvdX

In this episode, Marta Boffito, MD, PhD, FRCP, and Jens D. Lundgren, MD, DMSc, address key considerations when evaluating antiretroviral therapy safety and tolerability in aging patients and those with possible cardiometabolic toxicities, including:Monitoring for cardiometabolic syndromes (eg, lipid panels, coronary artery calcification scores)Approaching antiretroviral-related weight gain in clinical practiceInterpreting results from RESPOND on cardiovascular risk with integrase strand transfer inhibitorsCollaborating with other specialties (eg, cardiologists, dietitians) to provide a multidisciplinary approach for managing comorbidities, including prevention and managementFaculty: Marta Boffito, MD, PhD, FRCPConsultant Physician/ProfessorHIV/ResearchChelsea and Westminster HospitalImperial College LondonLondon, United KingdomJens D. Lundgren, MD, DMScProfessorRigshospital, University of Copenhagen DirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, DenmarkLink to full program:http://bit.ly/3PM3nYeLink to downloadable slides: http://bit.ly/3WgYycz

In this episode, Jens D. Lundgren, MD, DMSc, and Barbara Rath, MD, PhD, HDR, discuss emerging insights on outpatient management of acute COVID-19 and long COVID in Europe, including:Current COVID-19 variant and subvariant landscapeCOVID-19 treatments, including antivirals and monoclonal antibodiesESCMID COVID-19 treatment guidelinesLong COVID causes and pathophysiologyPrevention and management of long COVIDPresenters:Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, DenmarkBarbara Rath, MD, PhD, HDRCo-founder and Chair Vaccine Safety Initiative, Berlin, Germany/USAResearch DirectorUniversité de Bourgogne-Franche-Comté, FranceExecutive Board MemberESGREV (Respiratory Virus Study Group for ESCMID)ISIRV ChairISIRV-Epidemiology GroupFollow along with the downloadable slideset at:https://bit.ly/3IN1ScALink to full program: http://bit.ly/3kb8pn4

In this episode, Laurence Slama, MD, PhD, describes some of the ways that her clinic is attempting to make IM injections of long-acting antiretroviral therapy more sustainable long term. She explains the logistics of how she has allowed for patients to receive their long-acting cabotegravir and rilpivirine doses through community nurses after receiving the first 3 doses in a clinical setting. She also discusses some of the benefits and challenges of this kind of flexible system for patients and healthcare professionals. Laurence SlamaDoctorDepartment of Infectious DiseasesHôtel Dieu, APHPParis, FranceSee the full program at:https://bit.ly/3CsSvdX

In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:Providing gender-affirming careIntegrating PrEP and gender careTaking a sexual history and addressing sexual healthPrEP efficacy and options for transgender individuals, including FTC/TDF, FTC/TAF, and long-acting CABThe importance of reassuring transgender individuals that data suggest there are no drug–drug interactions between gender-affirming hormone therapy and any of the PrEP options Jill Blumenthal, MD, MAS (she/hers)Associate Professor of MedicineInfectious Diseases and Global Public HealthUniversity of California, San DiegoSan Diego, California See the full program at: https://bit.ly/3WhbBvZ

In this episode, Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, discusses optimizing HIV pre-exposure prophylaxis (PrEP) selection and persistence for men who have sex with men (MSM), including:Disparities in PrEP uptake for MSMWhat healthcare professionals can do to address disparities in PrEP uptakeProviding PrEP within a program that includes sexual health and primary care services, in addition to prescribing PrEPPrEP medication options for MSMHelping patients access PrEP medicationsBarriers to PrEP persistenceStrategies for aiding in PrEP persistence, including:          - Increasing access to healthcare professionals through text messaging and telemedicine         - Ensuring a welcome and sex-positive environment         - Partnering with pharmacists and community health workers for follow-up Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRNProfessorSchool of NursingJohns Hopkins UniversityNurse PractitionerDepartment of Infectious DiseasesJohn G. Bartlett Specialty PracticeBaltimore, Maryland See the full program at: https://bit.ly/3WhbBvZ

Fernando Carnavali, MD; Rasika Karnik, MS, MD; and Renslow Sherer, MD, discuss long COVID, including:Long COVID prevention strategies, including COVID-19 vaccinationLong COVID treatment approachesStrategies for management of patients with long COVIDPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite DirectorCOVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:Treatment resistance mechanismsCOVID-19 testingCOVID-19 treatments, including antivirals and monoclonal antibodiesPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite DirectorCOVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes a review of the following studies on ART and weight gain:ADVANCE: men vs women receiving DTG + FTC/TAF, DTG + FTC/TDF, and EFV + FTC/TDFComparison of ART regimens (eg, INSTI-, NNRTI- and PI-based regimens) in a pooled analysis of 8 phase III randomized controlled trialsGEMINI-1 and GEMINI-2: DTG + 3TC vs DTG + FTC/TDFPresenter:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3VIsDTgFollow along with the slides:https://bit.ly/3PYy1zn

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 rebound, including:Prevalence of COVID-19 reboundCOVID-19 rebound and antiviral useManagement of COVID-19 rebound Presenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes:DHHS Treatment Guideline recommendationsChoosing among first-line recommended integrase inhibitorsRecommended regimens for rapid ART startSelect key studies in treatment-naïve adults:AMBER study of virologic response with DRV/COBI/FTC/TAF vs DRV/COBI + TFC/TDFDRIVE-AHEAD and DRIVE-FORWARD efficacy study results, including resistance analyses of DOR + 2 NRTIs vs EFV or (DRV + RTV) + 2 NRTIsSafety and efficacy results from GEMINI-1 and GEMINI comparing DTG + 3TC vs DTG + FTC/TDFThe current/possible role of boosted PIs and NNRTIsSelection considerations between TDF and TAFPresenter:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3VIsDTgFollow along with the slides:https://bit.ly/3PYy1zn

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how to ethically prioritize patients for COVID-19 treatment when treatment supplies may be limited, including insights on:Risk stratificationMedication acquisitionDrug interactionsPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL

In this episode, Tamera Coyne-Beasley, MD, MPH, discusses strategies to address barriers to improve meningococcal vaccination rates by addressing social determinants of health and minimizing vaccine inequities, such as:Working closely with members of the community, including community-based organizations and adolescent and young adult influencersInvolving all youth when designing vaccination outreach and messaging programsCreating and evaluating the use of technologyUsing graphics, voices, and videos, appealing to all languages, and learning stylesAcknowledging that racism exists in medicine and medical historyInforming individuals that many children, including undocumented immigrants and those who are uninsured or underinsured, may be eligible for free meningococcal vaccines through the Vaccines for Children programSeeking ways to address the shortage of healthcare professionalsFaculty:Tamera Coyne-Beasley, MD, MPHDerrol Dawkins, MD Endowed Chair in Adolescent MedicineVice-Chair, PediatricsProfessor of Pediatrics and Internal MedicineDivision DirectorAdolescent MedicineUniversity of Alabama at BirminghamChildren's of AlabamaBirmingham, AlabamaLink to full program: https://bit.ly/3T0GLG2

Fernando Carnavali, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how new COVID-19 vaccines may affect risk stratification, including:Omicron-specific vaccineRole of vaccination in risk stratificationPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite Director COVID Center of Excellence Satellite-AnsoniaMount Sinai Health SystemNew York, New YorkRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious DiseasesPharmacyGrady Health SystemAtlanta, GeorgiaLink to slides:https://bit.ly/3WDYeFKLink to full program: https://bit.ly/3WJdIbs

In this episode,  an international expert panel shares their thoughts on what will be needed from future long-acting HIV treatment and prevention strategies to address populations who are not eligible for currently available long-acting options. The faculty members also discuss important considerations for leveraging long-acting HIV approaches to address care inequities across different populations.Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; essential considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection, such as the role of the lead-in phase, new guideline recommendations for monitoring during PrEP, and patient care and follow-up after PrEP discontinuation; and important considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium.Presenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3P3uPBc

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses improving HIV pre-exposure prophylaxis accessibility and availability for PWID, including by:Integrating PrEP with services that PWID are already aware of and/or connected to (eg, harm reduction/syringe services and substance use disorder treatment programs, peer-based training/education initiatives, healthcare for the homeless programs, and emergency departments) Staffing PrEP programs with people who are trusted by PWID and delivering PrEP in settings where patients feel respected, comfortable, and safe Tailoring prescribing practices and interventions (eg, same-day medication initiation, on-site pharmacies and/or medication storage, and intensive outreach and navigation) to support the care needs of PWIDCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficeAmerican Academy of HIV MedicineSee the full program at: https://bit.ly/3WhbBvZ

In this episode, Monica Gandhi, MD, MPH, and Chloe Orkin, MBChB, FRCP, MD, discuss considerations for monkeypox, now called mpox, in people with HIV, including:The history of monkeypox (mpox)The current monkeypox (mpox) outbreakWhat we knew about monkeypox (mpox) in PWH prior to the current outbreakData in PWH from an international case series of monkeypox (mpox)CDC data regarding monkeypox (mpox) in PWHMonkeypox (mpox) treatment recommendationsDrug–drug interaction considerations between tecovirimat for monkeypox (mpox) and ARTMonkeypox (mpox) vaccination recommendations for PWHGlobal access to monkeypox (mpox) treatments and vaccinesWhether monkeypox (mpox) is a sexually transmitted infection and the implications of thatOngoing research on monkeypox (mpox) in PWHMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineUniversity of California, San FranciscoMedical DirectorWard 86 HIV ClinicSan Francisco General Hospital San Francisco, CaliforniaChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomLink to full program:https://bit.ly/3HPu4Lk

In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancyWhat data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelinesAvailable data on newer ARVs in the ARV pregnancy registryPharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancyRecommendations for 2-drug ART regimens in pregnancyWhat to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelinesAnnette Haberl, MDPhysicianHead of HIV and WomenHIVCENTER FrankfurtDepartment of Infectious DiseaseHospital of the Johann Wolfgang Goethe UniversityFrankfurt, GermanyWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3HPu4Lk

In this episode, Stephane De Wit, MD, PhD, discusses the benefits of long-acting antiretroviral therapy (ART) for migrant populations in Europe—and specifically in Belgium. He also addresses some of the challenges of accessing and following up with those populations.Dr De Wit describes some of the ways that the Belgian healthcare system is set up to improve access to ART. He then explains some of the disease parameters for considering expanding the use of long-acting ART to patients who are not virologically suppressed. Finally, Dr De Wit offers some thoughts about the future of long-acting ART to migrant populations in Belgium.Stephane De Wit, MD, PhDFormer HeadInfectious DiseasesSaint Pierre University HospitalBrussels, BelgiumSee the full program at:https://bit.ly/3HIMAoF

When it comes to managing adults with HBV, should age factor into your treatment decision—or is it important to treat everyone, regardless of age?Listen as Dr George Lau discusses these questions and more for strategizing the monitoring and treatment of older adults with HBV. Presenter: George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA)ChairmanHumanity and Health Medical GroupHong Kong, ChinaChair, Professor, and Co-DirectorLiver Diseases & Transplant CentreThe Fifth Medical Centre of Chinese PLA General HospitalBeijing, ChinaLink to full program:https://bit.ly/3fg9fwB

In this episode, Nancy Reau, MD, and Coleman I. Smith, MD, discuss the burden of undiagnosed hepatitis delta virus (HDV) infection and who should be tested, including:Epidemiology of HDV infectionClinical course of HDV infectionPopulations at high risk of HDV infectionGuidelines for HDV testingFaculty: Nancy Reau, MDProfessor of MedicineChief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisColeman I. Smith, MDProfessor of MedicineHepatologistGeorgetown Transplant InstituteGeorgetown UniversityWashington, DCLink to full program: https://bit.ly/3WmJnziFollow along with the slides at:https://bit.ly/3NpAYI1

In this episode, Winnie Sseruma and Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, discuss some of the barriers to genuinely patient-centered HIV care in Africa and offer calls to action for healthcare professionals for responding to patient preferences.They discuss the efforts to improve patient-centered HIV care in the foundations and organizations for which they work. They also address issues related to stigma around HIV and complacency and lack of visibility for HIV.You will then hear them talk through differentiated service delivery in South Africa and Mozambique as models for other parts of Africa. They focus on HIV prevention and some of the difficulties of reaching certain populations to better communicate effective prevention practices.They end with a discussion about the importance of documenting the experiences and stories of people living with HIV.Winnie SserumaInternational Development Consultant London, United KingdomLinda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDDirectorDesmond Tutu HIV CentrePast PresidentInternational AIDS SocietyFaculty of Health SciencesUniversity of Cape TownCape Town, South AfricaLink to full program:https://bit.ly/3Fxsfkz

In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:Strategies on how to approach different ARV-related toxicitiesOther factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)Clinically relevant drug–drug interactions related to HIV and gender-affirming careMethods to reduce barriers to ART adherenceFaculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public HealthUniversity of California, San DiegoSan Diego, CaliforniaJennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoPharmacistWomen’s HIV ProgramUniversity of California San Francisco Medical CenterSan Francisco, CaliforniaLink to full program:https://bit.ly/3PM3nYeFollow along with the slides at:https://bit.ly/3NpAYI1

In this episode, Iskandar Azwa, MBChB, and patient advocate Andrew Tan Tze Tho discuss barriers to genuinely patient-centered HIV care in Malaysia and the surrounding region and offer calls to action for healthcare professionals for responding to patient preferences.They discuss health literacy programs and other forms of effective health communication, especially with respect to disparate communities. They also address the prevalence of late presentation in Malaysia and the importance of getting people tested and into care earlier.They then discuss the urgency of rapid initiation of antiretroviral therapy, discrepancies in access to health services, and stigma and discrimination.Finally, they discuss the issues preventing newer antiretrovirals from being more readily available to people in the region; the importance of maintaining and refining patient-focused, differentiated care in the face of such disparities; and the role of advocates and healthcare professionals in helping to drive those improvements. Iskandar Azwa, MBChBAssociate ProfessorInfectious Diseases, Faculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaAndrew Tan Tze ThoPresidentKuala Lumpur AIDS Support Services Society (KLASS)Kuala Lumpur, MalaysiaLink to full program:https://bit.ly/3Fxsfkz

In this episode, Nancy Reau, MD, shares her thoughts on the most practice-changing viral hepatitis data from AASLD 2022, including:Novel therapeutics for HBVHCV management strategiesHDV screening and linkage to careFatty liver disease in persons with viral hepatitisUse of statins to decrease morbidity and mortality in persons with liver diseasePresenter:Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate DirectorSolid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisLink to full program: https://bit.ly/3Y1tD6f

In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including: The role of novel β-lactam/β-lactamase inhibitor combinationsUse of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogensApplication of rapid diagnostic testing in critically ill patients with pneumonia, including current limitationsImplementation of advanced antibiograms and clinical prediction scoresClinical utility of biomarkers for pneumonia (eg, procalcitonin)Application of updated nosocomial pneumonia classifications in clinical practiceFaculty:Marion Elligsen, BScPhm, ​ MSc, RPh, ACPR​Practice-Based Researcher​Sunnybrook Research Institute​Antimicrobial Stewardship Pharmacy Lead​Department of Pharmacy​Sunnybrook Health Sciences Centre​Toronto, Ontario, Canada​Keith S. Kaye, MD, MPHChief  Division of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyAndrew Shorr, MD, MPH, MBA​Director​Pulmonary and Critical Care Medicine​Medstar Washington Hospital Center​Washington, DC​Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp. Link to full program:https://bit.ly/3HaZpYwLink to downloadable slideset:https://bit.ly/3UxHoqr

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:Hepatitis BPrevention of HBV vertical transmission when HBIg is unavailableTherapeutic vaccination for HBV cureAntiviral therapy to prevent HCC in patients with CHB in the indeterminate phaseHepatitis deltaHDV prevalence in ethnically diverse, urban, safety-net populationsBulevirtide ± pegIFN-α2a for chronic HDV in the French cATU studyBulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di studyHDV functional cure with lonafarnib-based therapyHepatitis CIntegrated community HCV service for PWUD: the ITTREAT studyHelios-3 study of treatment of people with HCV by specialists or nonspecialistsRisk of HCC after SVR in patients with HCVPresenter:Stefan Zeuzem, MDProfessor of MedicineChief, Department of Medicine I JW Goethe University Hospital Frankfurt, GermanyFollow along with the downloadable slideset at: https://bit.ly/3FxIOwZLink to full program: https://bit.ly/3Y1tD6f

In this episode,  Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, includingPrevention strategiesLA therapiesInvestigational agentsPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomBabafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on an online CME/CE program supported by an independent educational grant from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare. Link to full program:https://bit.ly/3iFEF0T

In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:  EPIC-HR study of nirmatrelvir plus ritonavirPINETREE study of remdesivirMOVe-OUT and Panoramic studies of molnupiravirCOVID-19 rebound in treated and untreated patientsPresenters:Jason Gallagher, PharmDClinical ProfessorSchool of PharmacyTemple UniversityClinical Pharmacy SpecialistInfectious DiseasesTemple University HospitalPhiladelphia, PennsylvaniaEmily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of Pharmacy Practice and ScienceUniversity of Maryland School of PharmacyInfectious Diseases Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, Maryland 

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:COVID-19 vaccines, including omicron BA.1 bivalent boosterRisk factors for breakthrough COVID-19 infectionsCOVID-19 diagnostics, including digital droplet PCRCOVID-19 therapeutics, including:Nirmatrelvir plus ritonavirTixagevimab plus cilgavimabBaricitinibTocilizumabInhaled interferon β-1aCOVID-19 therapeutics and outcomes in patients with immunocompromiseLong COVIDPresenters:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCPaul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women’s HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the downloadable slideset at:http://bit.ly/3gkJI67Link to full program:http://bit.ly/3TSVthM

In this episode, Nneka Holder, MD, MPH, shares various strategies to improve meningococcal vaccine uptake in adolescent patients, including: Use of school vaccine mandates beyond entry requirementsPromote more frequent visits by incorporating immunization platforms and using text or email reminders to bring patients back to the officeSchedule follow-up visits before patients leave the office to increase retentionIncrease access and convenience by:Implementing quick, immunization-only visitsPromoting use of alternative vaccinations sites (eg, school gyms, local pharmacies) for meningococcal booster dosesAddress vaccine hesitancy, ensuring patients and parents have a voice in how their healthcare is managedContinue to bring up the importance of meningococcal vaccines at every visit even after vaccine refusalFaculty: Nneka Holder, MD, MPHAssociate ProfessorDepartment of PediatricsMedStar Georgetown University HospitalWashington, DCLink to full program: https://bit.ly/3T0GLG2

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses solutions to expanding PrEP uptake. His discussion includes: Potential healthcare professional barriers to prescribing PrEPAddressing the gap in PrEP training for healthcare professionalsExpanding PrEP options to facilitate adherence and persistence: today and in the near futureImmediate PrEP initiation at New York City sexual health clinicsProviding PrEP by telehealthTake-home points on expanding PrEP uptakePresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses PrEP uptake for cisgender women. His discussion includes: Prevalence of PrEP use in cisgender women in the United StatesBarriers to PrEP uptake in cisgender womenImplementation of PrEP within family planning clinics in AtlantaPrEP in pregnancy and breastfeedingPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program: http://bit.ly/3UFUl2bFollow along with the slides at:http://bit.ly/3TDOPM8

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, focuses on transgender women. His discussion includes: Barriers to PrEP uptake in transgender womenHigh PrEP adherence among transgender women and transfeminine individuals in a real-world healthcare setting in New York CityPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake for people who inject drugs. His discussion includes: PrEP uptake and recommendations for people who inject drugsProject SHE: integrating PrEP with community-based syringe services for women who inject drugsPresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:http://bit.ly/3UFUl2bFollow along with the slides at:https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake in the context of racial inequities, specifically for Black and Latinx communities. His discussion includes: Inequities in PrEP uptake in Black and Hispanic and Latinx people compared with White peopleStructural barriers to PrEP adoptionKaiser Permanente study (2012-2019): PrEP continuum of care and new HIV infectionsEle[MEN]t study: PrEP persistence and discontinuation in young Black men who have sex with menCreating change: education of patients and healthcare professionals to address inequities in PrEP uptakePresenter: Timothy J. Wilkin, MD, MPHProfessor of MedicineDivision of Infectious DiseasesWeill Medical College of Cornell UniversityNew York, New YorkLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at: https://bit.ly/3EcaYg0

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including: Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)Risk factors for virologic failure of LA CAB + RPVThe ATLAS-2M studyCombined clinical trials of LA CAB + RPVPractical considerations for LA CAB + RPVImplementation of LA CAB + RPV Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension studySupporting candidates for LA antiretroviral therapy (ART)Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San FranciscoFuture LA ART The investigational LA HIV capsid inhibitor lenacapavir (LEN)LEN resistance from the CAPELLA and CALIBRATE studiesLEN injection-site reactions in the CAPELLA and CALIBRATE studiesPresenter: Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women’s HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at:http://bit.ly/3Gh9AKG